Tackling the cancer stem cells — what challenges do they pose? (original) (raw)

• Valent, P. et al. Cancer stem cell definitions and terminology: the devil is in the details. Nature Rev. Cancer 12, 767–775 (2012).
  Article CAS Google Scholar
• Wilson, E. B. The Cell in Development and Inheritance (ed. Osborn, H. F.) (The Macmillan Company, 1896).
  Google Scholar
• Pierce, G. B. & Speers, W. C. Tumors as caricatures of the process of tissue renewal: prospects for therapy by directing differentiation. Cancer Res. 48, 1996–2004 (1988).
  CAS PubMed Google Scholar
• Carney, D. N., Gazdar, A. F., Bunn, P. A. Jr & Guccion, J. G. Demonstration of the stem cell nature of clonogenic tumor cells from lung cancer patients. Stem Cells 1, 149–164 (1982).
  CAS PubMed Google Scholar
• Wiseman, D. H., Greystoke, B. F. & Somervaille, T. C. The variety of leukemic stem cells in myeloid malignancy. Oncogene http://dx.doi.org/10.1038/onc.2013.269 (2013).
• Vermeulen, L. et al. Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc. Natl Acad. Sci. USA 105, 13427–13432 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Marusyk, A., Almendro, V. & Polyak, K. Intra-tumour heterogeneity: a looking glass for cancer? Nature Rev. Cancer 12, 323–334 (2012).
  Article CAS Google Scholar
• Stephens, P. J. et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 486, 400–404 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Navin, N. et al. Tumour evolution inferred by single-cell sequencing. Nature 472, 90–94 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Kreso, A. & Dick, J. E. Evolution of the cancer stem cell model. Cell Stem Cell 14, 275–291 (2014).
  Article CAS PubMed Google Scholar
• Singh, S. K. et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 63, 5821–5828 (2003).
  CAS PubMed Google Scholar
• Eramo, A. et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 15, 504–514 (2008).
  Article CAS PubMed Google Scholar
• Hermann, P. C. et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1, 313–323 (2007).
  Article CAS PubMed Google Scholar
• Collins, A. T., Berry, P. A., Hyde, C., Stower, M. J. & Maitland, N. J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 65, 10946–10951 (2005).
  Article CAS PubMed Google Scholar
• Lee, A. et al. Isolation of neural stem cells from the postnatal cerebellum. Nature Neurosci. 8, 723–729 (2005).
  Article CAS PubMed Google Scholar
• Bussolati, B. et al. Isolation of renal progenitor cells from adult human kidney. Am. J. Pathol. 166, 545–555 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• am Esch, J. S. et al. Portal application of autologous CD133+ bone marrow cells to the liver: a novel concept to support hepatic regeneration. Stem Cells 23, 463–470 (2005).
  Article PubMed Google Scholar
• Richardson, G. D. et al. CD133, a novel marker for human prostatic epithelial stem cells. J. Cell Sci. 117, 3539–3545 (2004).
  Article CAS PubMed Google Scholar
• Cheung, A. M. et al. Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential. Leukemia 21, 1423–1430 (2007).
  Article CAS PubMed Google Scholar
• Ginestier, C. et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1, 555–567 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Carpentino, J. E. et al. Aldehyde dehydrogenase-expressing colon stem cells contribute to tumorigenesis in the transition from colitis to cancer. Cancer Res. 69, 8208–8215 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Ma, S. et al. Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Mol. Cancer Res. 6, 1146–1153 (2008).
  Article CAS PubMed Google Scholar
• Jiang, F. et al. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol. Cancer Res. 7, 330–338 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Rasheed, Z. A. et al. Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J. Natl Cancer Inst. 102, 340–351 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Goodell, M. A., Brose, K., Paradis, G., Conner, A. S. & Mulligan, R. C. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J. Exp. Med. 183, 1797–1806 (1996).
  Article CAS PubMed Google Scholar
• Li, R., Wu, X., Wei, H. & Tian, S. Characterization of side population cells isolated from the gastric cancer cell line SGC-7901. Oncol. Lett. 5, 877–883 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Li, X. X. et al. Emodin as an effective agent in targeting cancer stem-like side population cells of gallbladder carcinoma. Stem Cells Dev. 22, 554–566 (2013).
  Article CAS PubMed Google Scholar
• Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J. & Clarke, M. F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100, 3983–3988 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Kemper, K., Grandela, C. & Medema, J. P. Molecular identification and targeting of colorectal cancer stem cells. Oncotarget 1, 387–395 (2010).
  Article PubMed PubMed Central Google Scholar
• Vermeulen, L. et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nature Cell Biol. 12, 468–476 (2010).
  Article CAS PubMed Google Scholar
• Medema, J. P. Cancer stem cells: the challenges ahead. Nature Cell Biol. 15, 338–344 (2013).
  Article CAS PubMed Google Scholar
• Thiery, J. P. Epithelial-mesenchymal transitions in tumour progression. Nature Rev. Cancer 2, 442–454 (2002).
  Article CAS Google Scholar
• Nieto, M. A. The ins and outs of the epithelial to mesenchymal transition in health and disease. Annu. Rev. Cell Dev. Biol. 27, 347–376 (2011).
  Article CAS PubMed Google Scholar
• Puhr, M. et al. Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. Am. J. Pathol. 181, 2188–2201 (2012).
  Article CAS PubMed Google Scholar
• Rhim, A. D. et al. EMT and dissemination precede pancreatic tumor formation. Cell 148, 349–361 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Yu, M. et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339, 580–584 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Chen, J. et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488, 522–526 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• De Craene, B. & Berx, G. Regulatory networks defining EMT during cancer initiation and progression. Nature Rev. Cancer 13, 97–110 (2013).
  Article CAS Google Scholar
• Mani, S. A. et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704–715 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Morel, A. P. et al. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS ONE 3, e2888 (2008).
  Article PubMed PubMed Central CAS Google Scholar
• Guo, W. et al. Slug and Sox9 cooperatively determine the mammary stem cell state. Cell 148, 1015–1028 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Thiery, J. P., Acloque, H., Huang, R. Y. & Nieto, M. A. Epithelial-mesenchymal transitions in development and disease. Cell 139, 871–890 (2009).
  Article CAS PubMed Google Scholar
• Zavadil, J. & Bottinger, E. P. TGF-β and epithelial-to-mesenchymal transitions. Oncogene 24, 5764–5774 (2005).
  Article CAS PubMed Google Scholar
• Ellenrieder, V. et al. Transforming growth factor β1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Res. 61, 4222–4228 (2001).
  CAS PubMed Google Scholar
• Bakin, A. V., Rinehart, C., Tomlinson, A. K. & Arteaga, C. L. p38 mitogen-activated protein kinase is required for TGFβ-mediated fibroblastic transdifferentiation and cell migration. J. Cell Sci. 115, 3193–3206 (2002).
  CAS PubMed Google Scholar
• Masszi, A. et al. Integrity of cell-cell contacts is a critical regulator of TGF-β1-induced epithelial-to-myofibroblast transition: role for β-catenin. Am. J. Pathol. 165, 1955–1967 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Bakin, A. V., Tomlinson, A. K., Bhowmick, N. A., Moses, H. L. & Arteaga, C. L. Phosphatidylinositol 3-kinase function is required for transforming growth factor β-mediated epithelial to mesenchymal transition and cell migration. J. Biol. Chem. 275, 36803–36810 (2000).
  Article CAS PubMed Google Scholar
• Yook, J. I., Li, X. Y., Ota, I., Fearon, E. R. & Weiss, S. J. Wnt-dependent regulation of the E-cadherin repressor snail. J. Biol. Chem. 280, 11740–11748 (2005).
  Article CAS PubMed Google Scholar
• Yook, J. I. et al. A Wnt–Axin2–GSK3β cascade regulates Snail1 activity in breast cancer cells. Nature Cell Biol. 8, 1398–1406 (2006).
  Article CAS PubMed Google Scholar
• Scheel, C. et al. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 145, 926–940 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Li, H. J., Reinhardt, F., Herschman, H. R. & Weinberg, R. A. Cancer-stimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 signaling. Cancer Discov. 2, 840–855 (2012).
  Article CAS PubMed Google Scholar
• Liu, S. et al. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res. 66, 6063–6071 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Bouras, T. et al. Notch signaling regulates mammary stem cell function and luminal cell-fate commitment. Cell Stem Cell 3, 429–441 (2008).
  Article CAS PubMed Google Scholar
• Tam, W. L. et al. Protein kinase Cα is a central signaling node and therapeutic target for breast cancer stem cells. Cancer Cell 24, 347–364 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Celia-Terrassa, T. et al. Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells. J. Clin. Invest. 122, 1849–1868 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Battula, V. L. et al. Epithelial-mesenchymal transition-derived cells exhibit multilineage differentiation potential similar to mesenchymal stem cells. Stem Cells 28, 1435–1445 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Gupta, P. B. et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138, 645–659 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Kurrey, N. K. et al. Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells 27, 2059–2068 (2009).
  Article CAS PubMed Google Scholar
• Farmer, P. et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nature Med. 15, 68–74 (2009).
  Article CAS PubMed Google Scholar
• Moore, N. & Lyle, S. Quiescent, slow-cycling stem cell populations in cancer: a review of the evidence and discussion of significance. J. Oncol. 2011, 396076 (2011).
  Article PubMed CAS Google Scholar
• Anjomshoaa, A. et al. Slow proliferation as a biological feature of colorectal cancer metastasis. Br. J. Cancer 101, 822–828 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Roesch, A. et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 141, 583–594 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Pece, S. et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 140, 62–73 (2010).
  Article CAS PubMed Google Scholar
• Feuerhake, F., Sigg, W., Hofter, E. A., Dimpfl, T. & Welsch, U. Immunohistochemical analysis of Bcl-2 and Bax expression in relation to cell turnover and epithelial differentiation markers in the non-lactating human mammary gland epithelium. Cell Tissue Res. 299, 47–58 (2000).
  Article CAS PubMed Google Scholar
• Kondo, T., Setoguchi, T. & Taga, T. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc. Natl Acad. Sci. USA 101, 781–786 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Zhou, S. et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nature Med. 7, 1028–1034 (2001).
  Article CAS PubMed Google Scholar
• Brennan, K. R. & Brown, A. M. Wnt proteins in mammary development and cancer. J. Mammary Gland Biol. Neoplasia 9, 119–131 (2004).
  Article PubMed Google Scholar
• Tan, A. R., Alexe, G. & Reiss, M. Transforming growth factor-β signaling: emerging stem cell target in metastatic breast cancer? Breast Cancer Res. Treat. 115, 453–495 (2009).
  Article CAS PubMed Google Scholar
• Visnyei, K. et al. A molecular screening approach to identify and characterize inhibitors of glioblastoma stem cells. Mol. Cancer Ther. 10, 1818–1828 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Mezencev, R., Wang, L. & McDonald, J. F. Identification of inhibitors of ovarian cancer stem-like cells by high-throughput screening. J. Ovarian Res. 5, 30 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Carmody, L. C. et al. Phenotypic high-throughput screening elucidates target pathway in breast cancer stem cell-like cells. J. Biomolecular Screen. 17, 1204–1210 (2012).
  Article Google Scholar
• Sachlos, E. et al. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell 149, 1284–1297 (2012).
  Article CAS PubMed Google Scholar
• Chaffer, C. L. et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc. Natl Acad. Sci. USA 108, 7950–7955 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Gupta, P. B. et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 146, 633–644 (2011).
  Article CAS PubMed Google Scholar
• Mueller, M. M. & Fusenig, N. E. Friends or foes - bipolar effects of the tumour stroma in cancer. Nature Rev. Cancer 4, 839–849 (2004).
  Article CAS Google Scholar
• Hanahan, D. & Coussens, L. M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21, 309–322 (2012).
  Article CAS PubMed Google Scholar
• Lu, P., Weaver, V. M. & Werb, Z. The extracellular matrix: a dynamic niche in cancer progression. J. Cell Biol. 196, 395–406 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Liu, S. et al. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res. 71, 614–624 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Jinushi, M. et al. Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells. Proc. Natl Acad. Sci. USA 108, 12425–12430 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Yang, J. et al. Tumor-associated macrophages regulate murine breast cancer stem cells through a novel paracrine EGFR/Stat3/Sox-2 signaling pathway. Stem Cells 31, 248–258 (2013).
  Article CAS PubMed Google Scholar
• Marotta, L. L. et al. The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24− stem cell-like breast cancer cells in human tumors. J. Clin. Invest. 121, 2723–2735 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Ma, X. et al. A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE-mediated immunosuppression and inhibits breast cancer metastasis. Oncoimmunology 2, e22647 (2013).
  Article PubMed PubMed Central Google Scholar
• Lin, L. et al. The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-β signaling. Oncogene 28, 961–972 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Pinto, D., Gregorieff, A., Begthel, H. & Clevers, H. Canonical Wnt signals are essential for homeostasis of the intestinal epithelium. Genes Dev. 17, 1709–1713 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Booth, C., Brady, G. & Potten, C. S. Crowd control in the crypt. Nature Med. 8, 1360–1361 (2002).
  Article CAS PubMed Google Scholar
• Birnbaum, T. et al. Malignant gliomas actively recruit bone marrow stromal cells by secreting angiogenic cytokines. J. Neurooncol. 83, 241–247 (2007).
  Article CAS PubMed Google Scholar
• Lin, E. Y., Nguyen, A. V., Russell, R. G. & Pollard, J. W. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 193, 727–740 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Green, C. E. et al. Chemoattractant signaling between tumor cells and macrophages regulates cancer cell migration, metastasis and neovascularization. PLoS ONE 4, e6713 (2009).
  Article PubMed PubMed Central CAS Google Scholar
• Sica, A., Allavena, P. & Mantovani, A. Cancer related inflammation: the macrophage connection. Cancer Lett. 267, 204–215 (2008).
  Article CAS PubMed Google Scholar
• MacDonald, K. P. et al. An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation. Blood 116, 3955–3963 (2010).
  Article CAS PubMed Google Scholar
• DeNardo, D. G. et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 1, 54–67 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Vo, N. & Goodman, R. H. CREB-binding protein and p300 in transcriptional regulation. J. Biol. Chem. 276, 13505–13508 (2001).
  Article CAS PubMed Google Scholar
• Emami, K. H. et al. A small molecule inhibitor of β-catenin/CREB-binding protein transcription [corrected]. Proc. Natl Acad. Sci. USA 101, 12682–12687 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Chen, B. et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nature Chem. Biol. 5, 100–107 (2009).
  Article CAS Google Scholar
• Liu, J. et al. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc. Natl Acad. Sci. USA 110, 20224–20229 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Rosenbluh, J. et al. β-catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell 151, 1457–1473 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Anastas, J. N. & Moon, R. T. WNT signalling pathways as therapeutic targets in cancer. Nature Rev. Cancer 13, 11–26 (2013).
  Article CAS Google Scholar
• Katz, L. H. et al. Targeting TGF-β signaling in cancer. Expert Opin. Ther. Targets 17, 743–760 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Tremblay, M. R. et al. Discovery of a potent and orally active Hedgehog pathway antagonist (IPI-926). J. Med. Chem. 52, 4400–4418 (2009).
  Article CAS PubMed Google Scholar
• Jimeno, A. et al. Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clin. Cancer Res. 19, 2766–2774 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Graham, R. A. et al. Pharmacokinetics of Hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of α-1-acid glycoprotein binding. Clin. Cancer Res. 17, 2512–2520 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• LoRusso, P. M. et al. Phase I trial of Hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin. Cancer Res. 17, 2502–2511 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Krop, I. et al. Phase I pharmacologic and pharmacodynamic study of the γ secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J. Clin. Oncol. 30, 2307–2313 (2012).
  Article CAS PubMed Google Scholar
• Ridgway, J. et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 444, 1083–1087 (2006).
  Article CAS PubMed Google Scholar
• Hoey, T. et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 5, 168–177 (2009).
  Article CAS PubMed Google Scholar
• Warrell, R. P. Jr., de The, H., Wang, Z. Y. & Degos, L. Acute promyelocytic leukemia. N. Engl. J. Med. 329, 177–189 (1993).
  Article CAS PubMed Google Scholar
• Carey, J. O., Posekany, K. J., deVente, J. E., Pettit, G. R. & Ways, D. K. Phorbol ester-stimulated phosphorylation of PU.1: association with leukemic cell growth inhibition. Blood 87, 4316–4324 (1996).
  CAS PubMed Google Scholar
• Wu, H. et al. Reduction in lactate accumulation correlates with differentiation-induced terminal cell division of leukemia cells. Differentiation 48, 51–58 (1991).
  Article CAS PubMed Google Scholar
• Arcangeli, A. et al. Polar/apolar compounds induce leukemia cell differentiation by modulating cell-surface potential. Proc. Natl Acad. Sci. USA 90, 5858–5862 (1993).
  Article CAS PubMed PubMed Central Google Scholar
• Olsson, I., Gullberg, U., Ivhed, I. & Nilsson, K. Induction of differentiation of the human histiocytic lymphoma cell line U-937 by 1α, 25-dihydroxycholecalciferol. Cancer Res. 43, 5862–5867 (1983).
  CAS PubMed Google Scholar
• Munster, P. N. et al. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res. 61, 8492–8497 (2001).
  CAS PubMed Google Scholar
• Uchida, H., Maruyama, T., Nagashima, T., Asada, H. & Yoshimura, Y. Histone deacetylase inhibitors induce differentiation of human endometrial adenocarcinoma cells through up-regulation of glycodelin. Endocrinology 146, 5365–5373 (2005).
  Article CAS PubMed Google Scholar
• Momparler, R. L. Epigenetic therapy of cancer with 5-aza-2′-deoxycytidine (decitabine). Semin. Oncol. 32, 443–451 (2005).
  Article CAS PubMed Google Scholar
• Chi, P., Allis, C. D. & Wang, G. G. Covalent histone modifications — miswritten, misinterpreted and mis-erased in human cancers. Nature Rev. Cancer 10, 457–469 (2010).
  Article CAS Google Scholar
• Cao, Q. et al. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 27, 7274–7284 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• McCabe, M. T. et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492, 108–112 (2012).
  Article CAS PubMed Google Scholar
• Tam, W. L. & Weinberg, R. A. The epigenetics of epithelial-mesenchymal plasticity in cancer. Nature Med. 19, 1438–1449 (2013).
  Article CAS PubMed Google Scholar
• Krivtsov, A. V. et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 442, 818–822 (2006).
  Article CAS PubMed Google Scholar
• Bernt, K. M. et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 20, 66–78 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Daigle, S. R. et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20, 53–65 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Bhola, N. E. et al. TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer. J. Clin. Invest. 123, 1348–1358 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Ocana, O. H. et al. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell 22, 709–724 (2012).
  Article CAS PubMed Google Scholar
• Tsai, J. H., Donaher, J. L., Murphy, D. A., Chau, S. & Yang, J. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 22, 725–736 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nature Rev. Cancer 12, 252–264 (2012).
  Article CAS Google Scholar
• Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Leach, D. R., Krummel, M. F. & Allison, J. P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734–1736 (1996).
  Article CAS PubMed Google Scholar
• Yoshimura, A. & Muto, G. TGF-β function in immune suppression. Curr. Top. Microbiol. Immunol. 350, 127–147 (2011).
  CAS PubMed Google Scholar
• Wan, Y. Y. & Flavell, R. A. 'Yin-Yang' functions of transforming growth factor-β and T regulatory cells in immune regulation. Immunol. Rev. 220, 199–213 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Warburg, O., Wind, F. & Negelein, E. The metabolism of tumors in the body. J. Gen. Physiol. 8, 519–530 (1927).
  Article CAS PubMed PubMed Central Google Scholar
• Tennant, D. A., Duran, R. V. & Gottlieb, E. Targeting metabolic transformation for cancer therapy. Nature Rev. Cancer 10, 267–277 (2010).
  Article CAS Google Scholar
• Elstrom, R. L. et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 64, 3892–3899 (2004).
  Article CAS PubMed Google Scholar
• Ji, H. et al. LKB1 modulates lung cancer differentiation and metastasis. Nature 448, 807–810 (2007).
  Article CAS PubMed Google Scholar
• Christofk, H. R. et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452, 230–233 (2008).
  Article CAS PubMed Google Scholar
• Parsons, D. W. et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807–1812 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Mardis, E. R. et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 361, 1058–1066 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Yan, H. et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765–773 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Gross, S. et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J. Exp. Med. 207, 339–344 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Ward, P. S. et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17, 225–234 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Wouters, B. G. & Koritzinsky, M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nature Rev. Cancer 8, 851–864 (2008).
  Article CAS Google Scholar
• Cannito, S. et al. Redox mechanisms switch on hypoxia-dependent epithelial-mesenchymal transition in cancer cells. Carcinogenesis 29, 2267–2278 (2008).
  Article CAS PubMed Google Scholar
• Li, Z. & Rich, J. N. Hypoxia and hypoxia inducible factors in cancer stem cell maintenance. Curr. Top. Microbiol. Immunol. 345, 21–30 (2010).
  CAS PubMed Google Scholar
• Dong, C. et al. Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer Cell 23, 316–331 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Ginestier, C. et al. Mevalonate metabolism regulates basal breast cancer stem cells and is a potential therapeutic target. Stem Cells 30, 1327–1337 (2012).
  Article CAS PubMed Google Scholar
• Rangarajan, A. & Weinberg, R. A. Comparative biology of mouse versus human cells: modelling human cancer in mice. Nature Rev. Cancer 3, 952–959 (2003).
  Article CAS Google Scholar
• Hiramatsu, H. et al. Complete reconstitution of human lymphocytes from cord blood CD34+ cells using the NOD/SCID/γcnull mice model. Blood 102, 873–880 (2003).
  Article CAS PubMed Google Scholar
• Lapidot, T. et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367, 645–648 (1994).
  Article CAS PubMed Google Scholar
• Bonnet, D. & Dick, J. E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Med. 3, 730–737 (1997).
  Article CAS PubMed Google Scholar
• Bapat, S. A., Mali, A. M., Koppikar, C. B. & Kurrey, N. K. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res. 65, 3025–3029 (2005).
  Article CAS PubMed Google Scholar
• Dalerba, P. et al. Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl Acad. Sci. USA 104, 10158–10163 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Ricci-Vitiani, L. et al. Identification and expansion of human colon-cancer-initiating cells. Nature 445, 111–115 (2007).
  Article CAS PubMed Google Scholar
• O'Brien, C. A., Pollett, A., Gallinger, S. & Dick, J. E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445, 106–110 (2007).
  Article CAS PubMed Google Scholar
• Yang, Z. F. et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 13, 153–166 (2008).
  Article CAS PubMed Google Scholar
• Kelly, P. N., Dakic, A., Adams, J. M., Nutt, S. L. & Strasser, A. Tumor growth need not be driven by rare cancer stem cells. Science 317, 337 (2007).
  Article CAS PubMed Google Scholar
• Quintana, E. et al. Efficient tumour formation by single human melanoma cells. Nature 456, 593–598 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Deshpande, A. J. et al. Acute myeloid leukemia is propagated by a leukemic stem cell with lymphoid characteristics in a mouse model of CALM/AF10-positive leukemia. Cancer Cell 10, 363–374 (2006).
  Article CAS PubMed Google Scholar
• Cho, R. W. et al. Isolation and molecular characterization of cancer stem cells in MMTV-Wnt-1 murine breast tumors. Stem Cells 26, 364–371 (2008).
  Article CAS PubMed Google Scholar
• Driessens, G., Beck, B., Caauwe, A., Simons, B. D. & Blanpain, C. Defining the mode of tumour growth by clonal analysis. Nature 488, 527–530 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Barker, N. et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 449, 1003–1007 (2007).
  Article CAS PubMed Google Scholar
• Schepers, A. G. et al. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science 337, 730–735 (2012).
  Article CAS PubMed Google Scholar
• Zou, W. Regulatory T cells, tumour immunity and immunotherapy. Nature Rev. Immunol. 6, 295–307 (2006).
  Article CAS Google Scholar
• Restifo, N. P., Dudley, M. E. & Rosenberg, S. A. Adoptive immunotherapy for cancer: harnessing the T cell response. Nature Rev. Immunol. 12, 269–281 (2012).
  Article CAS Google Scholar
• Pollard, J. W. Tumour-educated macrophages promote tumour progression and metastasis. Nature Rev. Cancer 4, 71–78 (2004).
  Article CAS Google Scholar
• DeNardo, D. G. et al. CD4+ T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 16, 91–102 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Quante, M. et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 19, 257–272 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Dirat, B. et al. Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. Cancer Res. 71, 2455–2465 (2011).
  Article CAS PubMed Google Scholar
• Butler, J. M., Kobayashi, H. & Rafii, S. Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. Nature Rev. Cancer 10, 138–146 (2010).
  Article CAS Google Scholar
• Civin, C. I. et al. Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. J. Immunol. 133, 157–165 (1984).
  CAS PubMed Google Scholar
• Andrews, R. G., Singer, J. W. & Bernstein, I. D. Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties. J. Exp. Med. 169, 1721–1731 (1989).
  Article CAS PubMed Google Scholar
• Lin, G., Finger, E. & Gutierrez-Ramos, J. C. Expression of CD34 in endothelial cells, hematopoietic progenitors and nervous cells in fetal and adult mouse tissues. Eur. J. Immunol. 25, 1508–1516 (1995).
  Article CAS PubMed Google Scholar
• Healy, L. et al. The stem cell antigen CD34 functions as a regulator of hemopoietic cell adhesion. Proc. Natl Acad. Sci. USA 92, 12240–12244 (1995).
  Article CAS PubMed PubMed Central Google Scholar
• Ferrero, E. & Malavasi, F. The metamorphosis of a molecule: from soluble enzyme to the leukocyte receptor CD38. J. Leukoc. Biol. 65, 151–161 (1999).
  Article CAS PubMed Google Scholar
• Borland, G., Ross, J. A. & Guy, K. Forms and functions of CD44. Immunology 93, 139–148 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Ponta, H., Sherman, L. & Herrlich, P. A. CD44: from adhesion molecules to signalling regulators. Nature Rev. Mol. Cell Biol. 4, 33–45 (2003).
  Article CAS Google Scholar
• Takaishi, S. et al. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 27, 1006–1020 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Prince, M. E. et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc. Natl Acad. Sci. USA 104, 973–978 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Li, C. et al. Identification of pancreatic cancer stem cells. Cancer Res. 67, 1030–1037 (2007).
  Article CAS PubMed Google Scholar
• Kristiansen, G., Sammar, M. & Altevogt, P. Tumour biological aspects of CD24, a mucin-like adhesion molecule. J. Mol. Histol 35, 255–262 (2004).
  Article CAS PubMed Google Scholar
• Zhang, C., Li, C., He, F., Cai, Y. & Yang, H. Identification of CD44+CD24+ gastric cancer stem cells. J. Cancer Res. Clin. Oncol. 137, 1679–1686 (2011).
  Article CAS PubMed Google Scholar
• McKenzie, J. L. & Fabre, J. W. Human thy-1: unusual localization and possible functional significance in lymphoid tissues. J. Immunol. 126, 843–850 (1981).
  CAS PubMed Google Scholar
• Mayani, H. & Lansdorp, P. M. Thy-1 expression is linked to functional properties of primitive hematopoietic progenitor cells from human umbilical cord blood. Blood 83, 2410–2417 (1994).
  CAS PubMed Google Scholar
• Dominici, M. et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8, 315–317 (2006).
  Article CAS PubMed Google Scholar
• Wetzel, A. et al. Human Thy-1 (CD90) on activated endothelial cells is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18). J. Immunol. 172, 3850–3859 (2004).
  Article CAS PubMed Google Scholar
• Avalos, A. M., Labra, C. V., Quest, A. F. & Leyton, L. Signaling triggered by Thy-1 interaction with beta 3 integrin on astrocytes is an essential step towards unraveling neuronal Thy-1 function. Biol. Res. 35, 231–238 (2002).
  Article CAS PubMed Google Scholar
• Rege, T. A. & Hagood, J. S. Thy-1, a versatile modulator of signaling affecting cellular adhesion, proliferation, survival, and cytokine/growth factor responses. Biochim. Biophys. Acta 1763, 991–999 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Kroczek, R. A., Gunter, K. C., Germain, R. N. & Shevach, E. M. Thy-1 functions as a signal transduction molecule in T lymphocytes and transfected B lymphocytes. Nature 322, 181–184 (1986).
  Article CAS PubMed Google Scholar
• He, J. et al. CD90 is identified as a candidate marker for cancer stem cells in primary high-grade gliomas using tissue microarrays. Mol. Cell. Proteomics 11, M111.010744 (2012).
  Article PubMed CAS Google Scholar
• Yang, Z. F. et al. Identification of local and circulating cancer stem cells in human liver cancer. Hepatology 47, 919–928 (2008).
  Article CAS PubMed Google Scholar
• Donnenberg, V. S., Landreneau, R. J. & Donnenberg, A. D. Tumorigenic stem and progenitor cells: implications for the therapeutic index of anti-cancer agents. J. Control Release 122, 385–391 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Buhring, H. J. et al. Expression of novel surface antigens on early hematopoietic cells. Ann. NY Acad. Sci. 872, 25–38; discussion 38–39 (1999).
  Article CAS PubMed Google Scholar
• Gehling, U. M. et al. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood 95, 3106–3112 (2000).
  CAS PubMed Google Scholar
• Uchida, N. et al. Direct isolation of human central nervous system stem cells. Proc. Natl Acad. Sci. USA 97, 14720–14725 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Singh, S. K. et al. Identification of human brain tumour initiating cells. Nature 432, 396–401 (2004).
  Article CAS PubMed Google Scholar
• Rutella, S. et al. Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors. Clin. Cancer Res. 15, 4299–4311 (2009).
  Article CAS PubMed Google Scholar
• Ma, S. et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 132, 2542–2556 (2007).
  Article CAS PubMed Google Scholar
• Bertolini, G. et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc. Natl Acad. Sci. USA 106, 16281–16286 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Ferrandina, G. et al. Expression of CD133-1 and CD133-2 in ovarian cancer. Int. J. Gynecol. Cancer 18, 506–514 (2008).
  Article CAS PubMed Google Scholar
• Deng, S. et al. Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS ONE 5, e10277 (2010).
  Article PubMed PubMed Central CAS Google Scholar
• Marchitti, S. A., Brocker, C., Stagos, D. & Vasiliou, V. Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily. Expert Opin. Drug Metab. Toxicol. 4, 697–720 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Black, W. & Vasiliou, V. The aldehyde dehydrogenase gene superfamily resource center. Hum. Genom. 4, 136–142 (2009).
  Article CAS Google Scholar
• Huang, E. H. et al. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res. 69, 3382–3389 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Chen, Y. C. et al. Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer. Biochem. Biophys. Res. Commun. 385, 307–313 (2009).
  Article CAS PubMed Google Scholar
• Boonyaratanakornkit, J. B. et al. Selection of tumorigenic melanoma cells using ALDH. J. Invest. Dermatol. 130, 2799–2808 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Alvi, A. J. et al. Functional and molecular characterisation of mammary side population cells. Breast Cancer Res. 5, R1–R8 (2003).
  Article PubMed Google Scholar
• Dontu, G. et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 17, 1253–1270 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Majka, S. M. et al. Identification of novel resident pulmonary stem cells: form and function of the lung side population. Stem Cells 23, 1073–1081 (2005).
  Article PubMed Google Scholar
• Martin, C. M. et al. Persistent expression of the ATP-binding cassette transporter, Abcg2, identifies cardiac SP cells in the developing and adult heart. Dev. Biol. 265, 262–275 (2004).
  Article CAS PubMed Google Scholar
• Hussain, S. Z. et al. Side population cells derived from adult human liver generate hepatocyte-like cells in vitro. Dig. Dis. Sci. 50, 1755–1763 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Kim, M. & Morshead, C. M. Distinct populations of forebrain neural stem and progenitor cells can be isolated using side-population analysis. J. Neurosci. 23, 10703–10709 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Larderet, G. et al. Human side population keratinocytes exhibit long-term proliferative potential and a specific gene expression profile and can form a pluristratified epidermis. Stem Cells 24, 965–974 (2006).
  Article CAS PubMed Google Scholar
• Chua, C. et al. Characterization of a side population of astrocytoma cells in response to temozolomide. J. Neurosurg. 109, 856–866 (2008).
  Article CAS PubMed Google Scholar
• Haraguchi, N. et al. Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells 24, 506–513 (2006).
  Article CAS PubMed Google Scholar
• Bleau, A. M. et al. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 4, 226–235 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Chiba, T. et al. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 44, 240–251 (2006).
  Article CAS PubMed Google Scholar
• Ho, M. M., Ng, A. V., Lam, S. & Hung, J. Y. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res. 67, 4827–4833 (2007).
  Article CAS PubMed Google Scholar
• Mitsutake, N. et al. Characterization of side population in thyroid cancer cell lines: cancer stem-like cells are enriched partly but not exclusively. Endocrinology 148, 1797–1803 (2007).
  Article CAS PubMed Google Scholar
• Malanchi, I. et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 481, 85–89 (2012).
  Article CAS Google Scholar
• Yu, M. et al. RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature 487, 510–513 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Gonsalves, F. C. et al. An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway. Proc. Natl Acad. Sci. USA 108, 5954–5963 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Zhu, C. et al. Phosphosulindac (OXT-328) selectively targets breast cancer stem cells in vitro and in human breast cancer xenografts. Stem Cells 30, 2065–2075 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Huang, S. M. et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 461, 614–620 (2009).
  Article CAS PubMed Google Scholar
• Garber, K. Drugging the Wnt pathway: problems and progress. J. Natl Cancer Inst. 101, 548–550 (2009).
  Article PubMed Google Scholar
• Heidel, F. H. et al. Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CML. Cell Stem Cell 10, 412–424 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Yeung, J. et al. β-catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell 18, 606–618 (2010).
  Article CAS PubMed Google Scholar
• Malanchi, I. et al. Cutaneous cancer stem cell maintenance is dependent on β-catenin signalling. Nature 452, 650–653 (2008).
  Article CAS PubMed Google Scholar
• Bueno, L. et al. Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-β kinase antagonist, in mice. Eur. J. Cancer 44, 142–150 (2008).
  Article CAS PubMed Google Scholar
• Anido, J. et al. TGF-β receptor inhibitors target the CD44high/Id1high glioma-initiating cell population in human glioblastoma. Cancer Cell 18, 655–668 (2010).
  Article CAS PubMed Google Scholar
• Kabashima, A. et al. Side population of pancreatic cancer cells predominates in TGF-β-mediated epithelial to mesenchymal transition and invasion. Int. J. Cancer 124, 2771–2779 (2009).
  Article CAS PubMed Google Scholar
• Trachtman, H. et al. A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int. 79, 1236–1243 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Schlingensiepen, K. H. et al. Targeted tumor therapy with the TGF-β2 antisense compound AP 12009. Cytokine Growth Factor Rev. 17, 129–139 (2006).
  Article CAS PubMed Google Scholar
• Olson, R. E. & Albright, C. F. Recent progress in the medicinal chemistry of γ-secretase inhibitors. Curr. Top. Med. Chem. 8, 17–33 (2008).
  Article CAS PubMed Google Scholar
• Lanz, T. A. et al. Pharmacodynamics and pharmacokinetics of the γ-secretase inhibitor PF-3084014. J. Pharmacol. Exp. Ther. 334, 269–277 (2010).
  Article CAS PubMed Google Scholar
• Richter, S. et al. A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575). Invest. New Drugs 32, 243–249 (2013).
  Article PubMed PubMed Central CAS Google Scholar
• Harrison, H. et al. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res. 70, 709–718 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• McAuliffe, S. M. et al. Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc. Natl Acad. Sci. USA 109, E2939–E2948 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Zhu, T. S. et al. Endothelial cells create a stem cell niche in glioblastoma by providing NOTCH ligands that nurture self-renewal of cancer stem-like cells. Cancer Res. 71, 6061–6072 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Palagani, V. et al. Epithelial mesenchymal transition and pancreatic tumor initiating CD44+/EpCAM+ cells are inhibited by gamma-secretase inhibitor IX. PLoS ONE 7, e46514 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Jenkins, D. W. et al. MEDI0639: a novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivo. Mol. Cancer Ther. 11, 1650–1660 (2012).
  Article CAS PubMed Google Scholar
• Cooper, M. K., Porter, J. A., Young, K. E. & Beachy, P. A. Teratogen-mediated inhibition of target tissue response to Shh signaling. Science 280, 1603–1607 (1998).
  Article CAS PubMed Google Scholar
• Robarge, K. D. et al. GDC-0449 — a potent inhibitor of the hedgehog pathway. Bioorg. Med. Chem. Lett. 19, 5576–5581 (2009).
  Article CAS PubMed Google Scholar
• Buonamici, S. et al. Interfering with resistance to Smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci. Transl. Med. 2, 51ra70 (2010).
  Article PubMed PubMed Central CAS Google Scholar
• Clement, V., Sanchez, P., de Tribolet, N., Radovanovic, I. & Ruiz i Altaba, A. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr. Biol. 17, 165–172 (2007).
  Article CAS PubMed Google Scholar
• Bar, E. E. et al. Cyclopamine-mediated Hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells 25, 2524–2533 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Feldmann, G. et al. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res. 67, 2187–2196 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Dierks, C. et al. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 14, 238–249 (2008).
  Article CAS PubMed Google Scholar
• Peacock, C. D. et al. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc. Natl Acad. Sci. USA 104, 4048–4053 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Wallner, L. et al. Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. Cancer Res. 66, 3087–3095 (2006).
  Article CAS PubMed Google Scholar
• Nakashima, Y. et al. Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate. Mod. Rheumatol 20, 343–352 (2010).
  Article CAS PubMed Google Scholar
• Sherry, M. M., Reeves, A., Wu, J. K. & Cochran, B. H. STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells 27, 2383–2392 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Lin, L. et al. STAT3 is necessary for proliferation and survival in colon cancer-initiating cells. Cancer Res. 71, 7226–7237 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Hedvat, M. et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 16, 487–497 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Kroon, P. et al. JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells. Cancer Res. 73, 5288–5298 (2013).
  Article CAS PubMed Google Scholar
• Song, H., Wang, R., Wang, S. & Lin, J. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc. Natl Acad. Sci. USA 102, 4700–4705 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Debnath, B., Xu, S. & Neamati, N. Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein. J. Med. Chem. 55, 6645–6668 (2012).
  Article CAS PubMed Google Scholar
• Toullec, D. et al. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J. Biol. Chem. 266, 15771–15781 (1991).
  CAS PubMed Google Scholar
• Nemunaitis, J. et al. Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer. J. Clin. Oncol. 17, 3586–3595 (1999).
  Article CAS PubMed Google Scholar